The drug disrupts the iron-homeostasis regulator KH-type Splicing Regulatory Protein (KHSRP), triggers an unconventional ferroptotic cascade, and overcomes paclitaxel resistance in breast cancer [90]. Here, KHSRP is linked to breast carcinoma.